Abstract
Type 2 diabetes mellitus (T2DM) is a significiant risk factor for coronary artery disease (CAD). The landmark EMPA-REG trial demonstrated that SGLT2 inhibition significantly decreased the risk of all-cause mortality (number needed to treat: 39 at 3.1 years) in patients with T2DM and CAD.[1][1] In a
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the Royal College of Physicians of London
Paper Title
Journal
Date
